10-Q · May 14, 2026
MIRA Pharmaceuticals, Inc. reported no revenue for the quarter ended March 31, 2026, accompanied by a net loss of $1.15 million, an improvement from a net loss of $1.78 million in the same quarter of the previous year.…
Earnings analysis · 10-Q
MIRA earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
MIRA continued to report zero revenue for the quarter ended June 30, 2026 and a diluted EPS loss of -$0.03, with no quantitative guidance provided. The principal new development is a Nasdaq minimum-bid deficiency: the…
Read full summary
MIRA continued to report zero revenue for the quarter ended June 30, 2026 and a diluted EPS loss of -$0.03, with no quantitative guidance provided. The principal new development is a Nasdaq minimum-bid deficiency: the stock was below $1.00 for 30 consecutive business days, with compliance required by January 25, 2027. Potential delisting and associated financing and liquidity consequences materially worsen the risk profile.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.03
What stood out
-
Revenue Remains at Zero
The company reported zero revenue for the quarter ended June 30, 2026, with diluted EPS of -$0.03, unchanged from the prior quarter and improved from -$0.09 in the year-ago quarter.
-
Controls Remained Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the second quarter of 2026.
What to watch
-
Nasdaq Minimum-Bid Deficiency
On July 27, 2026, Nasdaq notified the company that its common stock had remained below the $1.00 minimum closing bid price for 30 consecutive business days. The company has until January 25, 2027, to regain compliance, requiring a closing bid price of at least $1.00 for 10 consecutive business days.
-
Potential Nasdaq Delisting
If compliance is not restored within the initial 180-calendar-day period ending January 25, 2027, the company may need to pursue an additional 180-calendar-day compliance period and potentially effect a reverse stock split; Nasdaq may ultimately delist the securities.
-
Intellectual Property Defense Costs
The filing states that the company anticipates expending significant financial and managerial resources to defend its intellectual property rights and against third-party infringement claims, creating a potential drain on resources while revenue remains zero.
Management's outlook
No quantitative revenue or EPS guidance was provided in the filing; forward outlook remains deferred.
Earlier filings 4
10-K · March 31, 2026
MIRA is a clinical‑stage biotech advancing three oral programs (Ketamir‑2, MIRA‑55, SKNY‑1). The company completed dosing in a randomized Phase 1 (SAD and MAD) study with a total of 56 participants and reports no…
10-Q · August 13, 2024
MIRA reported zero revenue and a widening net loss in Q2 2024: net loss of $1,691,325 (EPS $(0.11)) for the quarter and $(3,409,096) (EPS $(0.23)) for the six months. Cash declined to $2,823,781 at June 30, 2024 (down…
10-Q · May 13, 2024
MIRA reported a net loss of $1,717,771 (loss per share $0.12) for Q1 ended March 31, 2024, with zero revenue. Cash declined to $3,528,695 at quarter-end after using $1,049,536 in operating cash flow. Management…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.